Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Sections
    • Collections
  • Podcasts
  • Author Info
    • Overview for authors
    • Publication fees
    • Forms
    • Editorial policies
    • Submit a manuscript
    • Open access
  • Careers
  • Alerts
    • Email alerts
    • RSS
  • About
    • General information
    • Staff
    • Editorial Board
    • Contact
  • CMAJ JOURNALS
    • CMAJ
    • CMAJ Open
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CJS
  • CMAJ JOURNALS
    • CMAJ
    • CMAJ Open
    • JAMC
    • JPN
CJS

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Sections
    • Collections
  • Podcasts
  • Author Info
    • Overview for authors
    • Publication fees
    • Forms
    • Editorial policies
    • Submit a manuscript
    • Open access
  • Careers
  • Alerts
    • Email alerts
    • RSS
  • About
    • General information
    • Staff
    • Editorial Board
    • Contact
  • Subscribe to our alerts
  • RSS feeds
  • Follow CJS on Twitter
Case Note

Rofecoxib associated with diaphragm disease

Michael A. Lapner and Wesley J. Stephen
CAN J SURG December 01, 2007 50 (6) E27-E28;
Michael A. Lapner
Department of Surgery, McMaster University, Hamilton, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wesley J. Stephen
Department of Surgery, McMaster University, Hamilton, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Small-bowel obstruction secondary to circumferential strictures of the bowel lumen, also known as diaphragm disease, was originally reported as a congenital anomaly. Further research identified that webbing could be caused by other factors, and in 1973 the condition was correlated with nonsteroidal anti-inflammatory drug (NSAID) use.1 Aspirin has been used as an anti-inflammatory agent for over 100 years, and newer NSAIDs have been used since then. Recently, more selective cyclooxygenase (COX)-2 NSAIDs were released with the intention of minimizing gastrointestinal side effects.2 The following case report demonstrates an association between the COX-2 inhibitor rofecoxib and diaphragm disease of the small bowel.

Case report

A 52-year-old woman with a history of hysterectomy and rheumatoid arthritis presented in 2005 with recurrent smallbowel obstruction. Six years earlier, her rheumatoid arthritis had been initially treated with celecoxib. She had no history of NSAID use at that time. Her arthritis was unresponsive to the celecoxib, so 1 year later her medication was switched to rofecoxib. She was maintained on 25 mg/day of rofecoxib.

The patient suffered recurrent mechanical small-bowel obstruction beginning 14 months after the introduction of rofecoxib. Because of the chronic bowel obstructions, she underwent a laparotomy 2 years after the introduction of rofecoxib. A small-bowel stricture in the terminal ileum was identified and resected. The surgery was unsuccessful in preventing further small-bowel obstructions. Further investigations carried out at a tertiary centre gave negative results; the investigations included upper and lower gastrointestinal endoscopy and small-bowel imaging.

Because of the recurrent documented small-bowel obstructions, the patient underwent another laparotomy in August 2005. Inspection of the bowel and abdomen revealed no significant abnormalities such as adhesions or serosal pathology (Fig. 1). Intraoperative small-bowel endoscopy revealed an intraluminal stricture (diaphragm disease) (Fig. 2). This was managed with a small-bowel resection. At follow-up 20 months postoperatively, the patient had had no further bowel obstructions or gastrointestinal symptoms.1

FIG. 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG. 1

Normal bowel.

FIG. 2
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG. 2

Endoscopic examination of the small bowel showing an ileal stricture.

Discussion

NSAIDs act biochemically by inhibiting both COX-1 and COX-2 isoenzymes. COX-1 inhibition results in downregulation of prostaglandins, which have gastroprotective effects, and platelet production of thromboxane A2, which increases hemorrhagic risk.2 NSAIDs have been shown to cause an enteropathy, which is characterized by increased permeability and inflammation. Chronic inflammation may lead to ulceration and formation of a circumferential septum secondary to submucosal fibrosis.3 With the advent of a COX-2 selective NSAID, the risk of gastrointestinal and other side effects was hypothesized to be reduced.4 Cardiovascular side effects resulted in the withdrawal of rofecoxib from the market with the results of the APPROVe trial.5

In our report, a woman treated with rofecoxib had diaphragm disease. This suggests that there may be a direct or systemic cytotoxic effect of rofecoxib on gastrointestinal mucosa. Therefore, the selectivity of rofecoxib or other COX-2 medications may not be as effective as hypothesized. By preventing prostaglandin synthesis in gastrointestinal mucosal cells, the end result is stricture formation. The mechanism likely evolves from an initial insult to the bowel mucosa, producing an ulcer followed by subsequent repair through fibrosis. The circumferential nature might, in part, be explained by partial obstruction resulting in physical arrest of a pill, producing a nidus for direct ulceration. If enteric coated, the NSAID would theoretically be prevented from early metabolism, establishing a significant distal bowel ulceration followed by fibrosis. The only other documented report of COX-2 inhibitors and strictures was reported in a case report published in 2004.6 This study suggested a possible link between a COX-2 inhibitor and diaphragm disease.

This case report suggests a link between the COX-2 inhibitor rofecoxib and small-bowel diaphragm disease. It also reinforces previous claims that NSAID-induced diaphragm disease remains a difficult diagnosis — in our patient imaging, including enteroclysis and plain films, was unremarkable in the work-up of the small-bowel obstruction — and is best identified with endoscopy. Thus, for patients who present with small-bowel obstruction and are using COX-2 inhibitors, the differential diagnosis should include diaphragm disease.

Footnotes

  • Competing interests: None declared.

  • Accepted February 10, 2006.

References

  1. ↵
    1. Sturges HF,
    2. Krone CL
    . Ulceration and stricture of the jejunum in a patient on long-term indomethacin therapy. Am J Gastroenterol 1973;59:162–9.
    OpenUrlPubMed
  2. ↵
    1. Hawkey CJ
    . COX-2 inhibitors. Lancet 1999;353:307–14.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Lang J,
    2. Price AB,
    3. Levi AJ,
    4. et al
    . Diaphragm disease: pathology of disease of the small intestiine induced by non-steroidal antiinflammatory drugs. J Clin Pathol 1988; 41:516–26.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Lanas A,
    2. Ferrandez A
    . NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention. Chin J Dig Dis 2006;7:127–33.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Bresalier RS,
    2. Sandler RS,
    3. Quan H,
    4. et al
    . Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [published erratum appears in N Engl J Med 2006;355:221]. N Engl J Med 2005;352:1092–102.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Mir O,
    2. Dhote R,
    3. Scavennec R,
    4. et al
    . Cyclooxygenase 2 selective inhibitor induced bowel stricture: a case report [see comment]. Gut 2004;53:154. Comment in: Gut 2004;53:1057–8.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

Canadian Journal of Surgery: 50 (6)
CAN J SURG
Vol. 50, Issue 6
1 Dec 2007
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CJS.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Rofecoxib associated with diaphragm disease
(Your Name) has sent you a message from CJS
(Your Name) thought you would like to see the CJS web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Rofecoxib associated with diaphragm disease
Michael A. Lapner, Wesley J. Stephen
CAN J SURG Dec 2007, 50 (6) E27-E28;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Rofecoxib associated with diaphragm disease
Michael A. Lapner, Wesley J. Stephen
CAN J SURG Dec 2007, 50 (6) E27-E28;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Content

  • Current issue
  • Past issues
  • Collections
  • Alerts
  • RSS

Authors & Reviewers

  • Overview for Authors
  • Publication Fees
  • Forms
  • Editorial Policies
  • Submit a manuscript

About

  • General Information
  • Staff
  • Editorial Board
  • Contact Us
  • Advertising
  • Reprints
  • Copyright and Permissions
  • Accessibility
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 2291-0026

All editorial matter in CJS represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected].

View CMA's Accessibility policy.

Powered by HighWire